Non-invasive Ventilators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Non-invasive Ventilators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The non-invasive ventilators (NIV) market is expected to register a CAGR of 5.9% over the forecast period.

The onset of the COVID-19 pandemic had a significant impact on the market studied. Due to the sudden onset of the pandemic, a short-term negative impact was initially seen on the market, owing to the decreased patient visits to hospitals and clinics. However, the market witnessed immense growth in the later phases of the pandemic due to increased demand for NIV for COVID-19 patients and other chronic respiratory disease patients. As per a research study published in the Clinical Respiratory Journal in March 2021, along with continuous positive airway pressure (CPAP), NIV was widely used to treat patients with moderate to severe acute respiratory failure (ARF). Also, the researchers concluded that when a group of patients with moderate to severe COVID-19 infection were studied, NIV was successful in 48% of the total studied population, and a 57% survival rate was seen among the patients in the intensive care unit (ICU) incubation after NIV. Thus, due to the high survival rate among the target patients, the demand for the NIVs increased. This significantly contributed to the market's growth and is further expected to continue its growth trend during the forecast period.

Factors such as increasing cases of respiratory disorders and a rapid increase in demand for non-invasive procedures are anticipated to fuel the market growth during the forecast period. In addition, advantages associated with various types of non-invasive (NIV) ventilators are other factors associated with the increasing adoption of the devices and garnering the market's growth.

Chronic respiratory diseases affect the airways and other parts of the lungs. Respiratory symptoms are among the major causes of consultation with doctors and physicians in primary healthcare centers. Some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). These patients require ventilation for a better outcome. According to an article published in NCBI in June 2022, non-invasive positive pressure ventilation delivers oxygen into the lungs via positive pressure without the need for endotracheal intubation and is used in both acute and chronic respiratory failure.

In addition, as per an article published in the LLICM in June 2022, in post-operative hypoxemia, NIV has been successfully used. In addition, facemask NIV is known to improve gas exchange, reduce breathing issues and improve clinical outcomes in patients with hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD), obesity-hypoventilation, and in patients with cardiogenic pulmonary edema. Thus, due to the associated benefits of the systems, the adoption of these devices is increasing and expected to fuel the growth of the market.

However, complications and side effects associated with ventilators, such as the risk of being affected with pneumonia, might lower the adoption of the products, hindering the market's growth.

COPD is a progressive life-threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations. Moreover, serious illness may lead to an increasing need for emergency treatment for prolonged periods. In addition, asthma is one of the most common but complex heterogeneous inflammatory airway disorders seen among the target population. ​Thus, due to a high number of respiratory emergencies such as asthma and COPD, the application of NIV is expected to increase, thereby accelerating segmental growth.

According to an article published in the American Journal of Respiratory and Critical Care Medicine in September 2022, nearly 1 in 10 people are affected by COPD every year globally. In addition, as per the data published by the Global Initiative for Chronic Obstructive Lung Disease on World Lung Day 2022, nearly an estimated 200 million people had COPD in the previous year, and asthma is one of the most common respiratory diseases which affects approximately 262 million people annually. Various research suggests that NIV has more positive benefits for populations with asthma and COPD. Thus, the high burden of diseases is anticipated to create demand for the adoption of NIV and fuel the segment growth.

Additionally, according to an article published in the American Journal of Translational Research (AJTR) in May 2022, ipratropium bromide combined with non-invasive ventilation is effective in the treatment of patients with COPD and respiratory failure. The systems can significantly ameliorate circulatory inflammation and improve the pulmonary function and blood gas levels of patients and provide higher treatment efficacy. Thus, these benefits of the systems are anticipated to fuel the segment growth over the forecast period. Therefore, the advantages of the systems and applications in treating COPD patients are anticipated to create competitiveness among the players and contribute to the segment’s growth.

North America is expected to hold a major share of the market, and it is predicted to continue its growth over the forecast period. The major factors fuelling the market growth in the region are the increasing prevalence of various respiratory diseases and the growing number of product approvals.

Respiratory disease is one of the major causes of healthcare burden in the region, and asthma is one of the major diseases that affect the quality of life for most Americans. According to the January 2023 update by the American College of Allergy, Asthma & Immunology (ACAAI) organization, the annual hospitalization related to asthma is 439,000, and asthma accounts for nearly 1.3 million emergency room visits annually in the United States. In addition, as per the source above, the economic cost related to asthma is USD 56,000 million annually in the country.

Additionally, as per the January 2023 update by the Lung Canada organization, the rate of prevalence and incidence of asthma is among the highest in Canada, and about 2.7 million Canadians live with asthma every year. Also, as per the source above, asthma is the third crucial factor related to work time lost and school absenteeism coupled with hospitalization for children. The high prevalence of the diseases is anticipated to increase demand for NIV, thereby driving market growth in the region.

The global non-invasive ventilators market is highly competitive and consists of a number of major players. The major companies are focused on new product launches and the expansion of their product portfolio. The global and regional players focus on strategic activities such as partnership, collaboration, and acquisition. A few companies in the global market are ResMed Inc., Teleflex Incorporated, Hamilton Bonaduz AG, HEYER Medical AG, and Koninklijke Philips N.V., among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support